Related Experiment Videos
Delayed rejection after initial engraftment in non-myeloablative bone marrow transplantation
Muh-Hwa Yang1, Tzeon-Jye Chiou, Ta-Chung Chao
1Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|February 11, 2004
Summary
Non-myeloablative bone marrow transplantation (NM-BMT) can lead to delayed graft rejection in high-risk patients, even after initial successful engraftment. Further studies are needed to confirm NM-BMT suitability for these patient groups.
Area of Science:
- Hematology
- Transplantation Immunology
Background:
- Non-myeloablative bone marrow transplantation (NM-BMT) offers a safer alternative for hematological diseases and solid tumors, leveraging graft-versus-leukemia/tumor effects.
- This approach aims to reduce transplant-related mortality (TRM) and is considered relatively safe for elderly recipients.
Observation:
- This report details two cases of delayed graft rejection following initial successful engraftment in NM-BMT.
- Both patients, one with chronic myelogenous leukemia (CML) and another with myelodysplastic syndrome, experienced graft failure and subsequent mortality.
Findings:
- Case 1 involved HLA-matched unrelated-donor (MUD) BMT where pancytopenia emerged post-engraftment, with donor chimerism dropping significantly.
- Case 2, a sibling-donor transplant, also showed reduced donor chimerism and pancytopenia, leading to graft failure.
Implications:
- Delayed graft rejection is a significant concern in NM-BMT, particularly for high-risk patients like those receiving unrelated-donor transplants or elderly recipients.
- The findings underscore the need for further research to establish the safety and efficacy of NM-BMT in these specific patient populations.